RECEIVED CENTRAL FAX CENTER MAR 2 2 2407

REMARKS

USPTO/general

In accordance with the above amendments, claims 56-63, 67, 71-114, 119 and 124-125 have been withdrawn from consideration and claim 130 has been amended and new claim 131 has been added. Thus, claims 115, 116, 118, 120-121, 126-131 presently remain under consideration.

A supplemental species election has been required in the detailed Action. The applicants have been required to elect one specific agent or combinations of agents used to prepare $T_{\rm ck}$ cells, for example, from the agents recited in claims 129 and 130, such as one of the following:

- (1) IL-15;
- (2) IL-6, TNF and IL-2; or
- (3) IL-6, TNF and IL-15.

Pursuant to that requirement, applicants elect the combination of agents in species (2), i.e., IL-6, TNF and IL-2.

Applicants believe that claims 115, 116, 118, 120-121, 126-128 and 130 are readable on the elected species agents.

The above election is made with traverse inasmuch as applicants believe that the species are sufficiently closely related that they should be examined together.

Early examination of this application on the merits is respectfully requested.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.

USPTO/general

C. G. Mersereau

Registration No. 26205 900 Second Avenue South

Suite 820

Minneapolis, MN 55402

Telephone: (612) 339-7461

RECEIVED CENTRAL FAX CENTER

MAR 2 2 2007

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the foregoing Amendment to an Official Action dated February 22, 2007 and a Transmittal Letter in connection with application Serial No. 10/088,801 of inventor(s), Fionula M. Brennan et al., filed September 18, 2002, for "THERAPEUTIC METHODS AND COMPOUNDS" are being sent by facsimile transmission to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 22, 2007.

Barbara L. Davis

On Behalf of C. G. Mersereau

Date of Signature: March 22, 2007